Scientific Program

Saturday, 8th September 2007


7th Session:
Treatment of CNV I

Chairmen: Anton Haas (Graz, Austria))
Sebastian Wolf (Bern, Switzerland))
50   L Sebastian Wolf (Bern, Switzerland)
Angiography and OCT in the diagnosis and management of AMD
51   L Antonia M. Joussen (Düsseldorf, Germany)
Mechanism of Anti-VEGF therapies
52   L Salvatore Grisanti (Tübingen, Germany)
Update Pegabtanib
53   P Anton Haas, I. Steinbrugger, G. Mossböck, M. Weger, R. Maier, V. Gasser-Steiner (Graz, Austria)
Combined therapy with pegaptanib and anecortave acetate in patients with classic choroidal neovascularisation due to age-related macular degeneration
54   P Heinrich Heimann, N. Kumar, P. Lenfesty, S. Harding (Liverpool, Great Britain)
Treatment of retinal angimatous proliferations with intravitreal Pegaptanib
55   P Andreas Lipski, B. Jurklies, N. Bornfeld (Essen, Germany)
Predictive value of Multifocal Electroretinography in patients with exudative AMD and intravitreal treatment with pegaptanib sodium
56   L Norbert Bornfeld (Essen, Germany)
Update Ranibizumab
57   P Britta E. Heimes, G. Spital, M. Trieschmann, A. Lommatzsch, D. Pauleikhoff (Münster, Germany)
Which clinical factors are predictive for treatment effects after ranibizumab therapy?
58   P Christian Prünte, U. Schmidt-Erfurth (Vienna, Austria)
VEGF Trap in patients with neovascular age-related macular degeneration: Results of a phase II trial

Coffee break in the industrial exhibition area

8th Session:
Treatment of CNV II

Chairmen: Gabriel Coscas (Créteil, France)
Michael H. Foerster (Berlin, Germany)
59   P Ulrich Schraermeyer, P. Heiduschka (Tübingen, Germany)
Penetration of Bevacizumab (Avastin) through the retina after intravitreal injection in monkeys
60   L Focke Ziemssen, K.U. Bartz-Schmidt (Tübingen, Germany)
Update Bevacizumab: Safety
61   L Richard Spaide (New York, USA)
Avastin, Lucentis, Macugen - indications, management and practical clinical aspects
62   P Carsten H. Meyer, C. Chan, J. Gross, P. Abraham, A.S.D. Nuthi, G.T. Kokame, P.K. Kaiser, F.G. Holz (Bonn, Germany / Loma Linda, Palm Springs; Columbia, Aiea (Hawaii), USA)
Retinal pigment epithelial tears after intravitreal Bevacizumab injection for neovascular age-related macular degeneration
63   P Albrecht Lommatzsch, M. Gutfleisch, G. Spital, M. Trieschman, D. Pauleikhoff (Münster, Germany)
Comparison of PDT plus TA and anti-VEGF therapy in pigment epithelial detachments
64   P Victoria Hamelmann, H.-M. Helb, C. Meyer, F. G. Holz, N. Eter (Bonn, Germany)
Intravitreal bevacizumab for pigment epithelial detachments in age-related macular degeneration
65   P Sabine Aisenbrey, F. Gelisken, F. Ziemssen, K.U. Bartz-Schmidt (Tübingen, Germany)
Intravitreal bevacizumab for recurrent choroidal neovascularization after macular translocation surgery with 360-degree retinotomy
66   P Robert P. Finger, M. Fleckenstein, H.P.N. Scholl, F.G. Holz (Bonn, Germany)
Quality of life in age-related macular degeneration - a review of available psychometric tools
67   L Gisèle Soubrane (Créteil, France)
Antiangiogenic drugs for neovascular AMD: where are we now, where to go?

Lunch and coffee break

9th Session:
Treatment of CNV:
Combination strategies and surgical approaches

Chairmen: Bernd Kirchhof (Cologne, Germany)
Albert J. Augustin (Karlsruhe, Germany)
68   L Georg Spital (Münster, Germany)
Combination therapies in neovascular AMD - theory and clinical experience
69   L Albert J. Augustin (Karlsruhe, Germany)
Rationale and clinical results of a combination strategy with photodynamic therapy, bevacizumab and dexamethason for the treatment of exudative AMD
70   P Nicole Eter, V. Hamelmann, C.H. Meyer, M. Ladewig, F.G. Holz (Bonn / Saarbrücken, Germany)
Comparison between intravitreal bevacizumab monotherapy and combined treatment with photodynamic therapy for neovascular AMD
71   P Felix Gora, K. Gabriel, W. Lieb (Karlsruhe, Germany)
Intravitreal bevacizumab in combination with Verteporfin photodynamic therapy for predominantly classic subfoveal choroidal neovascularization associated with age-related macular degeneration
72   P Christoph Bitter, K. Suter, V. Figueiredo, C. Prünte, K. Hatz, C. Surber (Basel, Switzerland / Vienna, Austria)
Triamcinolone acetonide - preservative-free suspension for intravitreal injection.
73   P Katja Hatz, U. Schneider, C. Prünte (Basel, Switzerland / Vienna, Austria)
Visual outcome and central retinal thickness after combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of sub- and juxtafoveal choroidal neovascularisation in age related macular degeneration
74   L Bernd Kirchhof (Cologne, Germany)
Is there a place for surgical treatment in AMD?
75   P Greg Haverbeke, C. Claes (Antwerp, Belgium)
Full macular translocation in the era of intravitreal injections
75b   P Theodor Stappler¹, V. Borgioli², H. Heimann¹, D. Wong¹ (¹Liverpool, Great Britain / ²Florence, Italy)
Autofluorescence Findings in 360° Macular Translocation
76   P Gabriele Thumann, S. Kaempf, A. Salz, P.Walter (Aachen, Germany)
Tissue-engineered biodegradable pigment epithelial cell sheets for transplantation to the subretinal space. Experimental results
77   P Boris V. Stanzel, M. Englander, D. J. Strick, S. R. Stanislo, P. Huie, M. S. Blumenkranz, S. Binder, M.F. Marmor (Stanford, USA / Vienna, Austria / Bonn, Germany)
Towards prosthetic replacement of Bruch’s membrane: Comparison of polyester and electrospun nanofiber substrates
Frank G. Holz (Bonn, Germany)
Daniel Pauleikhoff (Münster, Germany)